Thrombosis and platelets: an update
| dc.contributor.author | Koupenova-Zamor, Milka | |
| dc.contributor.author | Kehrel, Beate E. | |
| dc.contributor.author | Corkrey, Heather A. | |
| dc.contributor.author | Freedman, Jane E. | |
| dc.date | 2022-08-11T08:09:20.000 | |
| dc.date.accessioned | 2022-08-23T16:27:02Z | |
| dc.date.available | 2022-08-23T16:27:02Z | |
| dc.date.issued | 2017-03-14 | |
| dc.date.submitted | 2017-02-16 | |
| dc.identifier.citation | Eur Heart J. 2017 Mar 14;38(11):785-791. doi: 10.1093/eurheartj/ehw550. <a href="https://doi.org/10.1093/eurheartj/ehw550">Link to article on publisher's site</a> | |
| dc.identifier.issn | 0195-668X (Linking) | |
| dc.identifier.doi | 10.1093/eurheartj/ehw550 | |
| dc.identifier.pmid | 28039338 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/36692 | |
| dc.description.abstract | Haemostasis and thrombosis are complex, multifactorial processes. There is an evolving understanding of the mechanisms influencing vascular occlusion and the role of inflammation and immunity. Despite major advances in elucidating the mechanistic pathways mediating platelet function and thrombosis, challenges in the treatment of vascular occlusive diseases persist. Pharmacological advances have greatly affected thrombotic outcomes, but this has led to the unwanted side effect of bleeding. Detailed assessment of the impact of non-thrombotic diseases on haemostasis and thrombosis is necessary to better evaluate thrombotic risk and establish optimal treatment. This review will focus on recent advances in understanding the contribution of evolving risk factors to thrombosis. | |
| dc.language.iso | en_US | |
| dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28039338&dopt=Abstract">Link to Article in PubMed</a> | |
| dc.relation.url | https://doi.org/10.1093/eurheartj/ehw550 | |
| dc.subject | Platelets | |
| dc.subject | Thrombosis | |
| dc.subject | Coagulation | |
| dc.subject | Cardiovascular | |
| dc.subject | Bleeding | |
| dc.subject | Biochemistry | |
| dc.subject | Cardiology | |
| dc.subject | Cell Biology | |
| dc.subject | Cellular and Molecular Physiology | |
| dc.subject | Molecular Biology | |
| dc.title | Thrombosis and platelets: an update | |
| dc.type | Journal Article | |
| dc.source.journaltitle | European heart journal | |
| dc.source.volume | 38 | |
| dc.source.issue | 11 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/metnet_pubs/6 | |
| dc.identifier.contextkey | 9698860 | |
| html.description.abstract | <p>Haemostasis and thrombosis are complex, multifactorial processes. There is an evolving understanding of the mechanisms influencing vascular occlusion and the role of inflammation and immunity. Despite major advances in elucidating the mechanistic pathways mediating platelet function and thrombosis, challenges in the treatment of vascular occlusive diseases persist. Pharmacological advances have greatly affected thrombotic outcomes, but this has led to the unwanted side effect of bleeding. Detailed assessment of the impact of non-thrombotic diseases on haemostasis and thrombosis is necessary to better evaluate thrombotic risk and establish optimal treatment. This review will focus on recent advances in understanding the contribution of evolving risk factors to thrombosis.</p> | |
| dc.identifier.submissionpath | metnet_pubs/6 | |
| dc.contributor.department | UMass Metabolic Network | |
| dc.contributor.department | Department of Medicine, Division of Cardiovascular Medicine | |
| dc.source.pages | 785-791 |